Published Jul 21, 2026, 6:45 AM ET · Updated 4 months ago · 1 source
US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom
bloomberg
·
Original Report
Axiom Biosciences is considering an initial public offering in Hong Kong, a rare move for an American biotechnology firm, and one that would help it tap China’s booming clinical development capabilities.